Inside a deal: Startup Tavros Therapeutics’ potential $403M collaboration
Durham-based biotechnology startup Tavros Therapeutics will partner with Bayer AG subsidiary Vividion Therapeutics to find new targets and treatments for cancer. Here’s a detailed look at the deal.
Read More
